aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Remix Therapeutics is a biotechnology company focused on developing novel small molecule therapies to reprogram RNA processing, aiming to treat diseases in entirely new ways. Their mission is to revolutionize disease treatment through innovative approaches to RNA biology, targeting a broad range of medical conditions.
The company has made significant strides in the biotech industry, leveraging cutting-edge research to create impactful therapies. Their work has garnered attention for its potential to transform medical treatment paradigms, positioning Remix Therapeutics as a leader in RNA-focused drug development.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Therapies
Technology
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Remix Therapeutics founded?
Remix Therapeutics was founded in 2018.
Where is Remix Therapeutics's headquarters located?
Remix Therapeutics's headquarters is located in Watertown, MA, US.
When was Remix Therapeutics's last funding round?
Remix Therapeutics's most recent funding round was for $60M (USD) in January 2024.
How many employees does Remix Therapeutics have?
Remix Therapeutics has 71 employees as of Feb 5, 2024.
How much has Remix Therapeutics raised to-date?
As of July 05, 2023, Remix Therapeutics has raised a total of $211M (USD) since Jan 3, 2024.
Add Comparison
Total Raised to Date
$211M
USD
Last Update Jan 3, 2024
Last Deal Details
$60M
USD
Jan 3, 2024
Series Unknown
Total Employees Over Time
71
As of Feb 2024
Remix Therapeutics Address
100 Forge Road
Watertown,
Massachusetts
02472
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts